The free ebook ‘Those Who Suffer Much, Know Much’ available from LDN
Research Trust in the UK contains 29 MS success stories presented as
patient case studies. The book features a treatment patients themselves say
is working for them, low doses of naltrexone (LDN)… or in other words,
extremely low doses of an old drug with a good safety profile but
unfortunately, unlike stem cells, one that happens to be long
out-of-patent.

Understandably, with no profit potential the health industry has expressed
zero interest in trialling this treatment, but even our health authorities
are ignoring the potential of this lower cost, lower risk treatment.

This response may well be deleted as many have been before, but at least
one more person will now be LDNAware.

(1) PILOT TRIAL NEWS – 1: Mult Scler. 2008 Sep;14(8):1076-83

A pilot trial of low-dose naltrexone in primary progressive multiple
sclerosis.

Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M,
Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi
M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.

Institute of Experimental Neurology (INSPE) and Department of Neurology,
San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy;
Fondazione Don Carlo Gnocchi, IRCCS, Milan, Italy.

A sixth month phase II multicenter-pilot trial with a low dose of the
opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with
primary progressive multiple sclerosis (PPMS).

The primary end points were safety and tolerability.

Secondary outcomes were efficacy on spasticity, pain, fatigue, depression,
and quality of life. Clinical and biochemical evaluations were serially
performed. Protein concentration of beta-endorphins (BE) and mRNA levels
and allelic variants of the mu-opiod receptor gene (OPRM1) were analyzed.

Five dropouts and two major adverse events occurred. The remaining adverse
events did not interfere with daily living. Neurological disability
progressed in only one patient.

A significant reduction of spasticity was measured at the end of the trial.
BE concentration increased during the trial, but no association was found
between OPRM1 variants and improvement of spasticity. Our data clearly
indicate that LDN is safe and well tolerated in patients with PPMS.

PMID: 18728058 PubMed – in process
http://www.ncbi.nlm.nih.gov/pubmed/18728058